Definitive Healthcare Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Definitive Healthcare Corp. on September 29, 2024, reporting a corporate governance event effective October 1, 2024. The filing details the promotion of an executive officer within the company's leadership team.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and personnel changes rather than financial performance.
Material Changes
The primary material change is the appointment of Kate Shamsuddin Jensen as Chief Operating Officer (COO), effective October 1, 2024. She was previously serving as Chief Strategy Officer since May 2024. Her compensation package includes:
- Base Salary: $360,000 annually.
- Performance Bonus: Target opportunity of 60% of base salary.
- Equity Grant: 113,379 time-vesting restricted stock units (RSUs) valued at $500,000.
- Vesting Schedule: 50% of RSUs vest on the first anniversary and 50% on the second anniversary of the effective date, contingent on continued service.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on market conditions, or discussion of risks and contingencies. The document is strictly a disclosure of the executive appointment and associated compensatory arrangements.
Investor Verification Checklist
- Confirm the effective date of the COO appointment (October 1, 2024).
- Verify the total value of the equity grant ($500,000) and the specific number of RSUs (113,379).
- Review the vesting schedule to understand the retention timeline for the new COO.
- Check subsequent filings for any impact on the company's equity dilution or compensation expense.